Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312294 | 0.77 | EGFR (0.38) | EGFR | |
| SCHEMBL2011130 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL1963573 | 0.75 | ADORA2A (0.36) | EGFR | |
| SCHEMBL277594 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL1586125 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL9652879 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL7948683 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL2141779 | 0.75 | EGFR (0.34) | EGFR | |
| SCHEMBL4957388 | 0.75 | KDM4E (0.38) | EGFR | |
| SCHEMBL788917 | 0.73 | PKN1 (0.33) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113416522-A | Low-conductivity anti-freezing cooling liquid for new energy power battery and preparation method thereof | 上海科鸿能源发展有限公司 | 2021-09-21 | — | — | CN | claimed |
| WO-2017062966-A1 | ANTIBODIES SPECIFIC FOR 4,6-DIAMINO-5-(FORMYULAMINO) PYRIMIDINE AND USES THEREOF | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2017-04-13 | — | — | WO | claimed |
| US-20050026862-A1 | Cosmetic or dermatological preparation | BEIERSDORF AG | 2005-02-03 | — | — | US | claimed |
| EP-1282680-A1 | COMPOSITIONS COMPRISING CYCLODEXTRIN | THE PROCTER & GAMBLE COMPANY (US) | 2003-02-12 | — | — | EP | claimed |
| US-6503413-B2 | Polyalkylene polysiloxane, buffering agent, aqueous carrier | THE PROCTER & GAMBLE COMPANY | 2003-01-07 | — | — | US | claimed |
| EP-1255806-A1 | STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| US-20020011584-A1 | Stable, aqueous compositions for treating surfaces, especially fabrics | THE PROCTOR & GAMBLE COMPANY | 2002-01-31 | — | — | US | claimed |
| US-20020010154-A1 | Compositions comprising cyclodextrin | THE PROCTER & GAMBLE COMPANY | 2002-01-24 | — | — | US | claimed |
| WO-2001088076-A1 | COMPOSITIONS COMPRISING CYCLODEXTRIN | THE PROCTER & GAMBLE COMPANY (US) | 2001-11-22 | — | — | WO | claimed |
| WO-2001060961-A1 | STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS | THE PROCTER & GAMBLE COMPANY (US) | 2001-08-23 | — | — | WO | claimed |
| EP-4652271-A1 | BASE EDITING-MEDIATED READTHROUGH OF PREMATURE TERMINATION CODONS (BERT) | The Broad Institute, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250339559-A1 | BASE EDITING-MEDIATED READTHROUGH OF PREMATURE TERMINATION CODONS (BERT) | THE BROAD INSTITUTE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3252172-B1 | FAST HYBRIDIZATION FOR NEXT GENERATION SEQUENCING TARGET ENRICHMENT | AGILENT TECHNOLOGIES INC (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118496292-A | Compounds and methods for reducing SNCA expression | IONIS制药公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2024155745-A1 | BASE EDITING-MEDIATED READTHROUGH OF PREMATURE TERMINATION CODONS (BERT) | THE BROAD INSTITUTE, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2001060961-A1 | STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS | THE PROCTER & GAMBLE COMPANY (US) | 2001-08-23 | — | — | WO | disclosed |
| EP-0479640-A2 | Novel phosphonate derivatives of certain nucleosides | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-04-08 | — | — | EP | disclosed |
| EP-0477454-A1 | Novel phosphonate derivatives of certain nucleosides | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-04-01 | — | — | EP | disclosed |
| EP-0335770-A2 | Novel fluorophosphonate nucleotide derivatives | MERRELL PHARMACEUTICALS INC. (US) | 1989-10-04 | — | — | EP | disclosed |
| US-4454133-A | REACTION PRODUCT OF GLUTARALDEHYDE AND CYCLIC AMIDE OR IMIDE | SUTTON LABORATORIES, INC. (US) | 1984-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010154-A1 | Compositions comprising cyclodextrin | FFAR4, FRG1, FGB | EGFR 568/4885PIK3CG 349/4885 |
| US-20050026862-A1 | Cosmetic or dermatological preparation | OGG1, UNG, MPG | EGFR 3085/4885PIK3CG 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.